| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 573,610 | 485,040 | ||
| Marketable securities | 218,277 | 198,885 | ||
| Prepaid expenses and other current assets | 14,376 | 14,025 | ||
| Total current assets | 806,263 | 697,950 | ||
| Property and equipmentat cost | 32,173 | - | ||
| Less accumulated depreciation and amortization | 8,201 | - | ||
| Property and equipment, net | 23,972 | 5,675 | ||
| Right-of-use assets | 21,818 | 22,859 | ||
| Restricted cash and other assets | 15,006 | 2,508 | ||
| Total assets | 867,059 | 728,992 | ||
| Accounts payable | 12,061 | 14,016 | ||
| Accrued expenses and other current liabilities | 42,749 | 22,454 | ||
| Lease liabilities | 5,039 | 5,002 | ||
| Total current liabilities | 59,849 | 41,472 | ||
| Principal term loan balance | 100,000 | - | ||
| Unamortized debt discount and issuance costs | 1,136 | - | ||
| Accrued end of term fee | 283 | - | ||
| Long-term debt, net | 99,147 | 98,813 | ||
| Lease liabilities, net of current portion | 16,280 | 17,262 | ||
| Total liabilities | 175,276 | 157,547 | ||
| Common stock, 0.0001 par value 200,000,000 shares authorized at september 30, 2025 and december 31, 2024 142,613,248 and 102,318,629 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 14 | 11 | ||
| Additional paid-in capital | 1,975,460 | 1,747,328 | ||
| Accumulated other comprehensive loss | 496 | 252 | ||
| Accumulated deficit | -1,284,187 | -1,176,146 | ||
| Total stockholders equity | 691,783 | 571,445 | ||
| Total liabilities and stockholders equity | 867,059 | 728,992 | ||
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)